

## Human and Mouse ORFeome Collaboration Clones


Distributed through K.K. DNAFORM

### Vector Map: pENTR/D-TOPO

**NAME:** pENTR/D-TOPO  
**RESISTANT MARKER:** Kanamycin resistant; 25 µg/ml  
**SOURCE:** Invitrogen Life Technologies  
**V\_TYPE:** Gateway entry vector  
**SEQUENCING PRIMERS:** **M13(-21)**, M13 reverse, **T7**

**Note the specific antibiotic to be used with this vector.**  
**Confirm sequencing primer sequences match vector before sequencing.**  
**Visit the homepage of Invitrogen for more information on this vector.**

#### Map



**POLYLINKER SEQUENCE:**

TAACGCTAGCATGGATGTTTTCCAGTCACGACGTT**GTAAAACGACGGCC**  
**AGT**CTTAAGCTCGGGCCCCAAATAATGATTTTTATTTTACTGATAGTGAC  
 CTGTTTCGTTGCAACAAATGATGAGCAATGCTTTTTTATAATGCCAACTT  
 TGTACAAAAAAGCAGGCTCCGCGGCCGCCCTTACC **-ORF-** AAGGGTG  
 GCGCGCCGACCCAGCTTCTTGTACAAAGTTGGCATTATAAGAAAGCAT  
 TGCTTATCAATTTGTTGCAACGAACAGGTCACTATCAGTCAAAATAAAAT  
 CATTATTTGCCATCCAGCTGATATC**CCCTATAGTGAGTCGTATTAC**ATGG  
 TCATAGCTGTTTTCTGGCAGCTCTG

**Sequence:**

1	CTTTCCTGCG	TTATCCCCTG	ATTCTGTGGA	TAACCGTATT	ACCGCCTTTG	AGTGAGCTGA	60
61	TACCGCTCGC	CGCAGCCGAA	CGACCGAGCG	CAGCGAGTCA	GTGAGCGAGG	AAGCGGAAGA	120
121	GCGCCCAATA	CGCAAACCGC	CTCTCCCCGC	GCGTTGGCCG	ATTCAATTAAT	GCAGCTGGCA	180
181	CGACAGGTTT	CCCAGCTGGA	AAGCGGGCAG	TGAGCGCAAC	GCAATTAATA	CGCGTACCGC	240
241	TAGCCAGGAA	GAGTTTGTAG	AAACGCAAAA	AGGCCATCCG	TCAGGATGGC	CTTCTGCTTA	300
301	GTTTGATGCC	TGGCAGTTTA	TGGCGGGCGT	CCTGCCCGCC	ACCCTCCGGG	CCGTTGCTTC	360
361	ACAACGTTCA	AATCCGCTCC	CGGCGGATTT	GTCTACTCA	GGAGAGCGTT	CACCGACAAA	420
421	CAACAGATAA	AACGAAAGGC	CCAGTCTTCC	GACTGAGCCT	TTCGTTTTAT	TTGATGCCTG	480
481	GCAGTTCCTC	ACTCTCGCGT	TAACGCTAGC	ATGGATGTTT	TCCCAGTCAC	GACGTTGTAA	540
541	AACGACGGCC	AGTCTTAAGC	TCGGGCCCCA	AATAATGATT	TTATTTTGAC	TGATAGTGAC	600
601	CTGTTTCGTTG	CAACAAATTG	ATGAGCAATG	CTTTTTTATA	ATGCCAACTT	TGTACAAAAA	660
661	AGCAGGCTCC	GCGGCCGCCC	CCTTCACCAA	GGGTGGGCGC	GCCGACCCAG	CTTTCTTGTA	720
721	CAAAGTTGGC	ATTATAAGAA	AGCATTGCTT	ATCAATTTGT	TGCAACGAAC	AGGTCATAT	780
781	CAGTCAAAAT	AAAATCATT	TTTGCCATCC	AGCTGATATC	CCCTATAGTG	AGTCGTATTA	840
841	CATGGTCATA	GCTGTTTCTT	GGCAGCTCTG	GCCCCGTGCT	CAAAATCTCT	GATGTTACAT	900
901	TGCACAAGAT	AAAAATATAT	CATCATGAAC	AATAAAACTG	TCTGCTTACA	TAAACAGTAA	960
961	TACAAGGGGT	GTTATGAGCC	ATATTCAACG	GGAAACGTCG	AGGCCGCGAT	TAAATTCCAA	1020
1021	CATGGATGCT	GATTTATATG	GGTATAAATG	GGCTCGCGAT	AATGTCGGGC	AATCAGGTGC	1080
1081	GACAATCTAT	CGCTTGTATG	GGAAGCCCGA	TGCGCCAGAG	TTGTTTCTGA	AACATGGCAA	1140
1141	AGGTAGCGTT	GCCAATGATG	TTACAGATGA	GATGGTCAGA	CTAAACTGGC	TGACGGAATT	1200
1201	TATGCCTCTT	CCGACCATCA	AGCATTTTAT	CCGTACTCCT	GATGATGCAT	GGTTACTCAC	1260
1261	CACTGCGATC	CCCGGAAAAA	CAGCATTTCCA	GGTATTAGAA	GAATATCCTG	ATTCAGGTGA	1320
1321	AAATATTGTT	GATGCGCTGG	CAGTGTTCCT	GCGCCGGTTG	CATTCGATTC	CTGTTTGTA	1380
1381	TTGTCCTTTT	AACAGCGATC	GCGTATTTCC	TCTCGCTCAG	GCGCAATCAC	GAATGAATA	1440
1441	CGGTTTGTTT	GATGCGAGTG	ATTTTGTATG	CGAGCGTAAT	GGCTGGCCTG	TTGAACAAGT	1500
1501	CTGGAAAGAA	ATGCATAAAC	TTTTGCCATT	CTCACCAGAT	TCAGTCGTCA	CTCATGTTGA	1560
1561	TTTCTCACTT	GATAACCCTA	TTTTTGCAGG	GGGGAAATTA	ATAGGTTGTA	TTGATGTTGG	1620
1621	ACGAGTCGGA	ATCGCAGACC	GATACCAGGA	TCTTGCCATC	CTATGGAACT	GCCTCGGTGA	1680
1681	GTTTTCTCCT	TCATTACAGA	AACGGCTTTT	TCAAAAATAT	GGTATTGATA	ATCCTGATAT	1740
1741	GAATAAATTG	CAGTTTCATT	TGATGCTCGA	TGAGTTTTTC	TAATCAGAAT	TGGTTAATTG	1800
1801	GTTGTAACAC	TGGCAGAGCA	TTACGCTGAC	TTGACGGGAC	GGCGCAAGCT	CATGACCAAA	1860
1861	ATCCCTTAAC	GTGAGTTACG	CGTCGTTCCA	CTGAGCGTCA	GACCCCGTAG	AAAAGATCAA	1920
1921	AGGATCTTCT	TGAGATCCTT	TTTTTCTGCG	CGTAATCTGC	TGCTTGCAAA	CAAAAAAACC	1980
1981	ACCGTACCA	GCGGTGGTTT	GTTTGCCGGA	TCAAGAGCTA	CCAACCTTTT	TTCCGAAGGT	2040
2041	AACTGGCTTC	AGCAGAGCGC	AGATAACAAA	TACTGTCTCT	CTAGTGTAGC	CGTAGTTAGG	2100
2101	CCACCCTTC	AAGAATCTTG	TAGCACCGCC	TACATACCTC	GCTCTGCTAA	TCCTGTTACC	2160
2161	AGTGGCTGCT	GCCAGTGGCG	ATAAGTCGTG	TCTTACCGGG	TTGGACTCAA	GACGATAGTT	2220
2221	ACCGGATAAG	GCGCAGCGGT	CGGGCTGAAC	GGGGGGTTTC	TGCACACAGC	CCAGCTTGGA	2280
2281	GCGAACGACC	TACACCGAAC	TGAGATACCT	ACAGCGTGAG	CATTGAGAAA	GCGCCACGCT	2340
2341	TCCCGAAGGG	AGAAAGGCGG	ACAGGTATCC	GGTAAGCGGC	AGGGTCGGAA	CAGGAGAGCG	2400
2401	CACGAGGGAG	CTTCCAGGGG	GAAACGCCTG	GTATCTTTAT	AGTCCTGTCT	GGTTTCGCCA	2460
2461	CCTCTGACTT	GAGCGTCGAT	TTTTGTGATG	CTCGTCAGGG	GGGCGGAGCC	TATGGAAAAA	2520
2521	CGCCAGCAAC	GCGGCCTTTT	TACGGTTTCT	GGCCTTTTGC	TGGCCTTTTG	CTCACATGTT	2580

All ORF clones are provided in Entry Vectors for the Invitrogen Gateway® cloning system. Invitrogen offers a whole range of Destination Vectors for a wide range of applications. Refer to the homepage of Invitrogen for further information on the Gateway® cloning system and related Invitrogen products at:

<http://www.invitrogen.com/content.cfm?pageid=4072>

For further information on the ORFeome Collaboration, visit their homepage at <http://www.orfeomecollaboration.org/html/index.shtml>.

For further technical information visit our homepage at: <http://www.dnaform.jp> or contact us under: [techinfo@dnaform.jp](mailto:techinfo@dnaform.jp).

## **Contact Address**

K.K. DNAFORM – *Precision Gene Technologies*  
Leading Venture Plaza-2  
75-1, Ono-cho, Tsurumi-ku, Yokohama City  
Kanagawa 230-0046  
Japan

Tel: +81-(0)45-510-0607  
Fax: +81-(0)45-510-0608  
e-mail: [techinfo@dnaform.jp](mailto:techinfo@dnaform.jp)  
Homepage: <http://www.dnaform.jp>